Prefer Newsweek on Google to see more of our trusted coverage when you search. Anthony Fauci has explained why the U.S isn't using ACAM2000—the smallpox vaccine that the U.S. has in a massive ...

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics ...

Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weapon Supports the government’s continued efforts and long-term strategy to maintain ...

On Wednesday, Emergent BioSolutions Inc. (NYSE:EBS) said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio. What ...

With global spread progressing around the United States and within North Carolina, there have been claims that a smallpox vaccine can be used to combat monkeypox. Claims regarding the effectiveness of ...

As the United States grapples with monkeypox, which has been declared a public health emergency, one of the key strategies that will be used to control its spread is vaccinating high-risk individuals.

CAMBRIDGE, England and CAMBRIDGE, Massachusetts, September 3 /PRNewswire-FirstCall/ -- Acambis plc (Acambis) , a leading vaccine company, announced today that the US ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) ...

Emergent BioSolutions has agreed to acquire the ACAM2000 ® [Smallpox (Vaccinia) Vaccine, Live] business of Sanofi Pasteur for up to $125 million cash, in a deal the buyer said would reinforce its ...

A Maryland life sciences company is acquiring a smallpox vaccine business from a French drug company in a deal worth up to $125 million. Emergent BioSolutions Inc., of Gaithersburg, has agreed to buy ...